Director Rogerio Vivaldi Coelho filed a Form 4 with the SEC on September 1, 2026, disclosing the cancellation of common stock, restricted stock units, and stock options in connection with the merger of Crinetics Pharmaceuticals, Inc. into a subsidiary of Vertex Pharmaceuticals Incorporated.
Key Highlights
- Merger effective date: The merger was reported as effective September 1, 2026, with Crinetics Pharmaceuticals surviving as a wholly owned subsidiary of Vertex Pharmaceuticals Incorporated.
- Merger consideration: Each share of common stock was canceled and converted into the right to receive $85.00 per share in cash, without interest and subject to applicable tax withholdings.
- Common stock disposed: 13,300 shares of common stock were disposed of at $85.00 per share, leaving a reported 0 shares beneficially owned directly.
- RSUs canceled: 5,925 restricted stock units, which vested immediately prior to the effective time, were canceled and converted into the right to receive $85.00 per unit in cash, less applicable tax withholding.
- Stock options canceled: Six tranches of stock options totaling 93,830 shares were canceled; those with exercise prices below $85.00 were converted into cash equal to the difference between $85.00 and the applicable exercise price, while any options with exercise prices at or above $85.00 were canceled for no consideration.
- Post-transaction ownership: Following all reported transactions, the reporting person held 0 shares of common stock and 0 derivative securities beneficially owned directly.
Merger Cancels All Equity Holdings of Crinetics Director Vivaldi Coelho
According to the filing, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) completed its merger on September 1, 2026, pursuant to an Agreement and Plan of Merger dated July 6, 2026, among Crinetics, Vertex Pharmaceuticals Incorporated, and Clark Merger Sub, Inc., a wholly owned subsidiary of Vertex. At the effective time of the merger, Merger Sub merged with and into Crinetics, with Crinetics surviving as a wholly owned subsidiary of Vertex.
The filing reports that director Rogerio Vivaldi Coelho disposed of 13,300 shares of common stock at $85.00 per share, reducing his direct beneficial ownership to 5,925 shares immediately after that transaction. A second transaction on the same date reflects the cancellation of 5,925 restricted stock units at $85.00 per unit. The filing states that each outstanding RSU that was not yet vested became immediately vested in full immediately prior to the effective time, after which all outstanding RSUs were canceled and converted into the right to receive the merger consideration in cash, less applicable tax withholding. Following this transaction, the reporting person held 0 shares directly.
In addition, six tranches of stock options were reported as disposed of on September 1, 2026, with exercise prices of $28.31, $18.29, $20.32, $44.71, $32.33, and $35.87 per share. The filing states that each option outstanding but not yet vested became immediately vested prior to the effective time. Options with per-share exercise prices below $85.00 were canceled and converted into the right to receive the difference between $85.00 and the applicable exercise price, less applicable tax withholding. The filing notes that the prices reported for these options reflect that difference. All option positions were reduced to 0 following the reported transactions. The form was signed by Tobin Schilke as attorney-in-fact on September 1, 2026.
What Was Disclosed
Director Rogerio Vivaldi Coelho reported the cancellation of all directly held common stock, restricted stock units, and stock options in Crinetics Pharmaceuticals as a result of the company's merger with a subsidiary of Vertex Pharmaceuticals, effective September 1, 2026, at $85.00 per share in cash.



Please wait processing your request...